Back | Next |
home / stock / celg / celg message board
Subject | By | Source | When |
---|---|---|---|
$CELG falling knife damn | Pennies_Envy | investorshub | 05/08/2018 5:03:53 PM |
$CELG remains volatile because of several product issues | joanne4trade | investorshub | 05/07/2018 3:59:42 PM |
$CELG has made mistake after mistake.. | biotech_researcher | investorshub | 05/02/2018 11:43:50 AM |
$CELG - Prothena Announces Global Neuroscience Research & | MinnieM | investorshub | 03/22/2018 12:24:05 AM |
Celgene Corp $CELG Is Trending Down, Know This Level | ITMS | investorshub | 03/20/2018 4:38:59 PM |
biotech 2050 (@Biotech2050) 3/12/18, 7:58 AM @tgtxdough $CELG #REVLIMID has | biotech_researcher | investorshub | 03/12/2018 1:49:02 PM |
$CELG 7 Companies We'd Buy and Hold for | BottomBounce | investorshub | 03/06/2018 10:37:29 PM |
Three huge screw ups recently. That huge swishing | biotech_researcher | investorshub | 02/28/2018 2:56:54 PM |
Rallying back hard... | biotech_researcher | investorshub | 12/12/2017 4:22:43 PM |
Looks like we've stopped falling, maybe. | shub | investorshub | 11/03/2017 5:16:59 PM |
Sold at limit sell 1.25 | dannyzee84 | investorshub | 10/26/2017 8:19:23 PM |
5 year low is around $50. Just dipped | PennyStocksGuru | investorshub | 10/26/2017 6:46:10 PM |
It was a great short at $140. | PennyStocksGuru | investorshub | 10/26/2017 6:44:25 PM |
It seems to me that the selloff is | shub | investorshub | 10/26/2017 6:28:09 PM |
Well there goes two years of solid gains. :( | Jld3294 | investorshub | 10/26/2017 6:11:14 PM |
In some 95p .9 short leash | dannyzee84 | investorshub | 10/26/2017 4:38:33 PM |
https://seekingalpha.com/article/4115337-celgene-dumps-chrons-disease-fight-yet | Inoviorulez | investorshub | 10/23/2017 10:45:39 AM |
Financial impact of stopping Crohn's disease trials. Many | NorFoster | investorshub | 10/20/2017 3:26:22 PM |
Celgene longs--be smart--move your biotech $$$$$$ to Anavex | plexrec | investorshub | 10/20/2017 1:07:44 PM |
Noticed AH drop in share price, thank you. | north40000 | investorshub | 10/19/2017 9:58:10 PM |
News, Short Squeeze, Breakout and More Instantly...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...